The factors affecting early death in newly diagnosed APL patients
Open Access
- 1 January 2019
- journal article
- research article
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 14 (1) , 647-652
Abstract
Background and aim: In the past, acute promyelocytic leukemia (APL) was considered as one of the most rapidly lethal form of acute myeloid leukemia (AML). The objective of this study was to assess clinical parameters affecting early death (ED) in patients with APL. Materials and methods: Forty-three patients with APL who were diagnosed at Hacettepe University Hospital between the years of 2005 and 2018 were evaluated. Results: In univariate analyses, presentation with hemorrhage, DIC or infection at diagnosis, ECOG performance score, blast percentage on bone marrow, Sanz score, leukocyte, thrombocyte, fibrinogen and LDH levels were found to be statistically significantly different between patients with ER and patients without ED. In multivariate analysis, presentation with hemorrhage, DIC or infection at diagnosis, ECOG performance score, blast percentage on bone marrow, Sanz score, leukocyte, thrombocyte, fibrinogen, and LDH levels were found to be independent factors that are related with higher rate of ED in 30 days after treatment. Conclusion: Induction chemotherapy should be started as soon as possible after diagnosis of APL. Improving ED rates may become the greatest challenge for the future treatment of the diseases.Keywords
This publication has 24 references indexed in Scilit:
- Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidBlood, 2011
- Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia RegistryLeukemia, 2011
- All Trans Retinoic Acid and CancerImmunopharmacology and Immunotoxicology, 2010
- Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeYearbook of Oncology, 2010
- High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCGLeukemia, 2009
- Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA GroupBlood, 2008
- Acute Promyelocytic Leukemia: Recent Advances in Diagnosis and ManagementSeminars in Oncology, 2008
- Acute promyelocytic leukemia: from highly fatal to highly curableBlood, 2008
- Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcomeEuropean Journal of Haematology, 2006
- Early haemorrhagic morbidity and mortality during remission induction with or without all‐trans retinoic acid in acute promyelocytic leukaemiaBritish Journal of Haematology, 2000